BCR and melanoma: Furthermore, impairment of NFAT activity facilitates leukemia cell elimination by the BCR-ABL inhibitor dasatinib, and NFAT inhibition augments the anti-cancer effects of vemurafenib and trametinib in melanoma [31, 32].